Altered Immunoregulation in Rheumatoid Arthritis: The Role of Regulatory T Cells and Proinflammatory Th17 Cells and Therapeutic Implications

<div>Therapeutic targeting of Treg and Th17 cells in rheumatoid arthritis (RA). The figure displays currently employed therapeutic approaches in RA for which an effect on Treg and Th17 cells has been reported in the literature (see text for details). Other compounds depicted in the figure are currently under investigation in RA or have been tested in experimental models of the disease. CTLA-4: cytotoxic T lymphocyte antigen 4; IL: interleukin; TGF-<i>β</i>: transforming growth factor-<i>β</i>; TNF: tumor necrosis factor.</div>

Mediators of Inflammation

fig1

Figure 1

Figure 1: Altered Immunoregulation in Rheumatoid Arthritis: The Role of Regulatory T Cells and Proinflammatory Th17 Cells and Therapeutic Implications 

Figure 1 | Altered Immunoregulation in Rheumatoid Arthritis: The Role of Regulatory T Cells and Proinflammatory Th17 Cells and Therapeutic Implications 